Revisiting Cannabinoid Therapeutics for Pain

Chronic joint pain, muscle pain, inflammation, musculoskeletal disorders, and impaired muscle recovery have become growing health concerns that contribute significantly to global disability. Osteoarthritis (OA) alone is predicted to affect nearly 1 billion people worldwide by 2050. As a result, demand for effective strategies to manage joint pain and inflammation continues to rise.

Why look for alternatives to traditional pain medications?

The current pain-management landscape is dominated by nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. NSAIDs remain widely used for arthritis, chronic pain relief, and inflammation. Prolonged use increases gastrointestinal toxicity risks while causing cardiovascular complications and harmful effects on kidney function and overall health.

In more severe cases, opioid analgesics are used for pain and inflammation management. Opioids may provide short-term analgesic benefits, but they carry significant risks related to tolerance, dependency, and long-term safety. Moreover, there is growing regulatory scrutiny surrounding the prescription of opioids.

Topical pain-relief formulations have emerged as alternatives to oral NSAIDs as they may reduce systemic exposure and associated adverse effects. However, the skin barrier, tissue penetration, and formulation efficacy remain significant challenges.

In addition, conventional supplements such as glucosamine have shown mixed clinical outcomes due to variable absorption, bioavailability, and formulation differences. Therapeutic outcomes may also depend heavily on formulation design, delivery system, and tissue penetration efficiency.

These limitations have increased research on safer, more targeted approaches to managing chronic joint and muscle pain while supporting muscle recovery, particularly therapies capable of modulating multiple inflammatory and pain-signaling pathways simultaneously.

Cannabidiol in Pain Management: Benefits and Challenges

Cannabinoids are a diverse group of bioactive compounds derived from the Cannabis sativa plant, and they are increasingly being studied for chronic pain management. Among the cannabinoids, cannabidiol (CBD) does not have the intoxicating effects that are associated with tetrahydrocannabinol (THC). Because of this, CBD has gained significant attention for therapeutic applications in pain and inflammation management, including muscle pain and recovery support.

CBD binds to CB1 receptors in the brain and nervous system, regulating pain signals, mood, memory, and neural activity effectively. Cannabinoids activate CB1 receptors, regulating neurotransmitters that reduce pain perception and calm excessive nerve signaling throughout the central nervous system.

Research has explored the potential use of CBD in osteoarthritis-related joint pain, inflammatory pain, neuropathic pain, muscle pain, and chronic musculoskeletal disorders. However, clinical outcomes remain variable due to differences in formulation, dosing, and bioavailability.

CBD, like other cannabinoids, is highly lipophilic and not water-soluble, which makes effective therapeutic delivery difficult. CBD’s poor aqueous solubility limits dissolution and absorption, reducing bioavailability and making it difficult to achieve consistent systemic exposure. This results in variability in permeation across biological membranes, affecting the predictability of onset, duration, and overall efficacy in pain management applications. As a result, its dosing remains inconsistent across delivery formats, and it faces formulation-dependent limitations in achieving reliable, reproducible clinical outcomes.

Trait Bioscience: Taking CBD directly to your pain points

Trait Bioscience has addressed this limitation by developing a game-changing technology that converts hemp-derived, water-insoluble cannabinoids into fully water-soluble forms, rather than relying on water-compatible emulsions or suspensions. This scientific innovation directly targets the long-standing challenges associated with CBD as a pain medication: poor bioavailability, limited membrane permeability, and inconsistent absorption.

By addressing the solubility issue, this technology can help the body absorb cannabinoids more effectively, leading to more consistent dosing. Trait Biosciences’ new approach could unlock the health potential of CBD-based therapies for pain management in clinical settings.

CBD82S: A promising water-soluble CBD

Trait Bioscience’s CBD82S is a glycosylated, water-soluble CBD created by the enzymatic addition of glucose to hemp-derived CBD. It also dissolves easily in propylene glycol and vegetable glycerin, without the need for oils or emulsifiers. CBD82S meets GMP standards, avoids additives and particles, and supports topical, oral, inhalable, injectable, and adaptable therapeutic delivery methods effectively. Additionally, it supports sterile manufacturing processes and offers a shelf life of up to 12 months.

Trait’s CBD significantly reduces joint pain and improves mobility in dogs and cats, supported by strong preliminary clinical research data.

The promising results observed in pet dogs and cats suggest translational potential for human applications, particularly for conditions associated with chronic joint pain and inflammation. These findings may support future use in arthritis and topical pain relief, as well as broader chronic pain management strategies aimed at improving mobility and musculoskeletal function.

Preclinical and clinical evaluations of CBD82S have also demonstrated a favorable safety and efficacy profile across multiple delivery formats. Oral studies in mouse and minipig models reported no significant adverse events; topical human studies showed no sensitization or irritation after 21 days of application, and extended-use studies also confirmed good skin tolerability after more than 12 weeks of continuous use.

In efficacy assessments, CBD82S demonstrated enhanced permeation across skin, intestinal, and buccal tissues, indicating improved biological delivery potential. Topical applications improved joint comfort and function while reducing pain and inflammation in exploratory studies involving animals and human participants. Oral administration in mouse models showed relaxation-related effects and reduced anxiety-associated activity.

Final Thoughts:

The future of pain management and muscle recovery will depend on therapies that can balance efficacy, safety, and targeted delivery. Advances in water-soluble cannabinoid technologies may help improve bioavailability, dosing precision, and delivery versatility across oral, topical, and transdermal applications. Continued clinical validation and formulation innovation will be critical in determining how cannabinoid-based therapies integrate into mainstream pain management strategies.

Trait CBD, with its improved absorption and therapeutic reliability, can expand the role of cannabinoids in arthritis pain relief, chronic pain management, and recovery-focused applications. This could potentially shape a new generation of non-opioid pain therapeutics.

Revisiting Cannabinoid Therapeutics for Pain: CBD, THC & Modern Pain Relief